131875-08-6 Usage
General Description
Lexacalcitol is a synthetic analog of vitamin D that is primarily used for the treatment of hyperparathyroidism and secondary hyperparathyroidism in patients with chronic kidney disease. It works by binding to the vitamin D receptors in the parathyroid glands, leading to a decrease in parathyroid hormone levels and a reduction in the release of calcium and phosphorus from the bones. This helps to maintain normal levels of these minerals in the blood and prevent the development of bone disorders such as osteoporosis. Lexacalcitol is administered orally and has been shown to be effective in lowering parathyroid hormone levels and improving bone health in patients with chronic kidney disease. However, it may also cause side effects such as gastrointestinal disturbances, headaches, and skin rashes, so it should be used with caution and under the guidance of a healthcare professional.
Check Digit Verification of cas no
The CAS Registry Mumber 131875-08-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,8,7 and 5 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 131875-08:
(8*1)+(7*3)+(6*1)+(5*8)+(4*7)+(3*5)+(2*0)+(1*8)=126
126 % 10 = 6
So 131875-08-6 is a valid CAS Registry Number.
InChI:InChI=1/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1
131875-08-6Relevant articles and documents
Highly potent cell differentiation-inducing analogues of 1α,25-dihydroxyvitamin D3: Synthesis and biological activity of 2-methyl-1,25-dihydroxyvitamin D3 with side-chain modifications
Fujishima, Toshie,Zhaopeng, Liu,Konno, Katsuhiro,Nakagawa, Kimie,Okano, Toshio,Yamaguchi, Kentaro,Takayama, Hiroaki
, p. 525 - 535 (2007/10/03)
Eight 2-methyl substituted analogues of 20-epi-22R-methyl-1α,25-dihydroxyvitamin D3 (5) and 20-epi-24,26,27-trihomo-22-oxa-1α,25-dihydroxyvitamin D3 (6: KH-1060) were convergently synthesized. Preparation of the CD-ring portions with modified side chains of 5 and 6, followed by palladium-catalyzed cross-coupling with the A-ring enyne synthons (20a-d), (3S,4S,5R)-, (3S,4R,5R)-, (3S,4S,5S)- and (3R,4R,5S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methyloct-1-en-7-yne, afforded two sets of four A-ring stereoisomers of 20-epi-2,22-dimethyl-1,25-dihydroxyvitamin D3 (7a-d) and 20-epi-24,26,27-trihomo-2-methyl-22-oxa-1,25-dihydroxyvitamin D3 (8a-d). The biological profiles of the hybrid analogues were assessed in terms of affinity for vitamin D receptor (VDR) and HL-60 cell differentiation-inducing activity in comparison with the natural hormone. The combined modifications of the A-ring at the 2-position and the side chain yielded analogues with high potency.